Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 5/20 | 0.32 |
| ▸ | TDO2 | P48775 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25890671 | 0.96 | KMT2A (0.37) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL16202457 | 0.84 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL25891385 | 0.83 | TDO2 (0.35) | SMN1; SMN2KDM4EHTTNOTUMHSD17B3 | |
| SCHEMBL25892503 | 0.83 | SMN1; SMN2 (0.31) | SMN1; SMN2KDM4EHTT | |
| SCHEMBL19604359 | 0.83 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL18179935 | 0.82 | KMT2A (0.40) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL14296207 | 0.79 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL26298233 | 0.79 | MEN1 (0.34) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL23027271 | 0.79 | NOTUM (0.45) | KMT2AMEN1SMN1; SMN2KDM4EHTT | |
| SCHEMBL21366311 | 0.78 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235082-A1 | SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME | FUT5, FUT6, SIGLEC7 | KMT2A 2082/4885MEN1 2127/4885SMN1; SMN2 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.